<DOC>
	<DOCNO>NCT00907699</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood tissue patient cancer laboratory may help doctor learn change occur DNA RNA identify biomarkers related cancer . PURPOSE : This laboratory study look biomarkers tumor tissue blood sample patient non-small cell lung cancer .</brief_summary>
	<brief_title>Laboratory Study Using Samples From Patients With Non-Small Cell Lung Cancer Treated Clinical Trial CASE-2507</brief_title>
	<detailed_description>OBJECTIVES : Primary - Identify mutation epidermal growth factor receptor ( EGFR ) non-small cell lung cancer specimens clinical trial CASE-2507 . - Investigate EGFR DNA copy-number change . - Determine abnormality pathway , c-MET PI3K pathways potential mechanism resistance . OUTLINE : This multicenter study . DNA RNA extract tumor sample . Genomic DNA analyze use real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis order study resistance mechanism secondary EGFR mutation c-MET PI3K pathway . RNA analyze use TaqMan quantitative PCR order determine copy number EGFR express tissue . Peripheral blood sample use isolate peripheral blood mononuclear cell positive epithelial cell adhesion molecule ( EpCAM ) .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Eligible concurrently enrol clinical trial CASE2507 PATIENT CHARACTERISTICS : Willing able comply schedule visit , treatment plan , laboratory test , study procedure Normal coagulation profile platelet count &gt; 100,000/mmÂ³* Not pregnant NOTE : *For patient second biopsy procedure already time progression erlotinib hydrochloride therapy require research biopsy . PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent anticoagulant ( e.g. , warfarin lowmolecular weight heparin ) No concurrent antiplatelet therapy ( e.g. , aspirin , clopidogrel , antiplatelet agent ) * NOTE : *For patient second biopsy procedure already time progression erlotinib hydrochloride therapy require research biopsy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>